EFFECTS OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH THE METABOLIC SYNDROME

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该研究的目的是确定根据NCEP标准定义的肿瘤坏死因子-α阻断对代谢综合征患者的影响。以前的研究已经提出了一个潜在的“脂肪-血管”轴，即由脂肪细胞来源的细胞因子引发的炎症，从而触发动脉粥样硬化的发展。我们假设代谢综合征患者阻断肿瘤坏死因子-α将积极影响心脏风险的炎症标记物，如内皮功能和糖耐量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine the effect of TNF-alpha blockade in patients with Metabolic Syndrome, as defined by the NCEP criteria. Previous studies have suggested a potential "adipo-vascular" axis, the initiation of inflammation from adipocyte derived cytokins which trigger the development of atherosclerosis. We hypothesize TNF-alpha blockade in patients with metabolic syndrome will positively affect inflammatory markers of cardiac risk such as endothelial function and glucose tolerance.